January 23, 2018Open Access

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer

Key Points

Key points are not available for this paper at this time.

Abstract

T cells expressing higher levels of PD1 which can be modulated by anti-PD1. These data set the scene for clinical evaluation of denosumab use in patients receiving contemporary immune checkpoint blockade.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Ahern et al. (Tue,) studied this question.

synapsesocial.com/papers/6a03ad9228e1c76df7f016b8 https://doi.org/https://doi.org/10.1080/2162402x.2018.1431088

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Kinetics of costimulatory molecule expression by T cells and dendritic cells during the induction of tolerance versus immunity <i>in vivo</i>2005 · 72 citations
2Progression to androgen insensitivity in a novelin vitro mouse model for prostate cancer1995 · 120 citations
3RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase2014 · 49 citations
4PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma2014 · 3,550 citations
5A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD12015 · 241 citations

Demander à l'IA

Bookmark

View Full Paper